Companies: 10,795·Total market cap: $144.5T
BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

BBIONASDAQHealthcare● Active
$67.61
+$0.28(+0.42%)
Market Cap$13.2B
P/E Ratio
52W High$84.94
52W Low$37.69
Overview

BridgeBio Pharma, Inc. (BBIO) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BBIO · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-3.75bbio eps ttm · bbio earnings per shareEarnings history
PE Ratio (TTM)bbio pe ratio ttm · bbio price to earningsPE Ratio deep dive
Revenue (TTM)$580.0Mbbio revenue ttm · bbio annual revenueFull revenue history
Dividend YieldNo Dividenddoes bbio pay dividends · bbio dividend yieldDividend history
Shares Outstanding197.2Mbbio shares outstanding · bbio floatShares outstanding history
Next EarningsAug 4, 2026Est.bbio earnings date · bbio next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$502.1M▲ +126.26% YoY
202320242025
bridgebio pharma, inc. revenue · bbio revenue 2025
FY 2025Net Income-$729.3M▼ 36.12% YoY
202320242025
bridgebio pharma, inc. net income · bbio profit 2025
FY 2025EPS$-3.79▼ 31.60% YoY
202320242025
bbio eps · bridgebio pharma, inc. earnings per share 2025
TTM:Revenue: $580.0MNet Income: -$725.9MEPS: $-3.75View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy26 analystsis bbio a buy · bbio analyst rating
Strong Buy
0
Buy
24
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$83.00Low
$67.61Current
$105.21Avg Target55.61% upside
$157.00High
bbio price target · bbio 12 month forecast

Total: 26 · Buy rate: 92.3%

The BBIO analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month price target is $105.21, representing +55.61% upside from the current price of $67.61.

Stock Performance

Full History
1D+0.42%
1W+6.59%
1M+0.33%
3M+3.44%
YTD-11.61%
1Y+73.23%
5Y+8.47%

About BridgeBio Pharma, Inc.

CEONeil Kumar
IPO DateJun 27, 2019
Employees725
CountryUS

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candida…

what is bridgebio pharma, inc. · bbio stock overview · bridgebio pharma, inc. company profile · who is bridgebio pharma, inc. ceo · bbio NASDAQ · bridgebio pharma, inc. headquarters · bridgebio pharma, inc. business segments

About Stock Overview & Key Data

BridgeBio Pharma, Inc. (BBIO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 27, 2019. As of the latest trading session, BBIO stock price is $67.61, with a market capitalization of $13.2B. The stock has returned +73.23% over the past 12 months and -11.61% year-to-date.

According to 26 Wall Street analysts, the consensus rating for BridgeBio Pharma, Inc. stock is Buy, with an average 12-month price target of $105.21. In fiscal year 2025, BridgeBio Pharma, Inc. reported revenue of $502.1M and net income of -$729.3M. For detailed data — including BridgeBio Pharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, BridgeBio Pharma, Inc. (BBIO) stock price is $67.61. The stock is traded on NASDAQ under the ticker symbol BBIO. The 52-week range is $37.69 – $84.94.

BBIO stock priceBBIO quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice